Curium moved into definitive acquisition talks, agreeing to buy Lantheus for up to about $8 billion, a deal structured around a $102.50 per-share closing price plus contingent value rights tied to product sales. The agreement aims to strengthen Curium’s US theranostics manufacturing platform and broaden its radiodiagnostics reach, while Lantheus brings radiopharma oncology and precision diagnostics—components that could accelerate commercial scaling in key nuclear medicine categories. In parallel, Supernus Pharmaceuticals and Indivior Pharmaceuticals announced a tax-free, all-stock “merger of equals” to form a CNS-focused company with 11 marketed neurological products, expected to close in the fourth quarter of 2026. The combined firm will be led under the Supernus name and supported by structural synergies, with Indivior’s Sublocade highlighted as a key commercial anchor as the new CNS portfolio takes shape.